AZ194

AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM) . AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects[1].

Product Specifications

CAS Number

[2241651-99-8]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/az194.html

Purity

99.83

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C(N1CCC(CC1)C2=NC3=C(N2CC4=CC(F)=CC=C4)C=CC=C3)C5=CC=C(C(OC)=C5)OCC6=CC(F)=CC=C6

Molecular Formula

C34H31F2N3O3

Molecular Weight

567.63

Precautions

H315, H319

References & Citations

[1]Cai S, et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Sci Transl Med. 2021;13 (619) :eabh1314.